Literature DB >> 22427594

Comparison of formalin-fixed and snap-frozen samples analyzed by multiplex ligation-dependent probe amplification for prognostic testing in uveal melanoma.

Sarah L Lake1, Helen Kalirai, Justyna Dopierala, Bertil E Damato, Sarah E Coupland.   

Abstract

PURPOSE: Survival of patients with uveal melanoma (UM) correlates strongly with chromosomal abnormalities, such as monosomy 3 and polysomy 8q. Studies have shown multiplex ligation-dependent probe amplification (MLPA) to detect reliably chromosomal aberrations in UM using frozen samples. To date, the concordance between MLPA data generated from frozen and fixed samples has not been investigated. Our study aimed to compare MLPA data obtained from fixed and frozen tissues to determine whether fixed samples can be used in UM genetic prognostic testing.
METHODS: Adjacent samples were taken from 20 UM cases, with one sample being snap-frozen, and the second being formalin-fixed and paraffin-embedded (FFPE). MLPA analysis was performed using the P027.B1 assay. The chromosome arm copy numbers obtained for each pair of UM samples then were compared.
RESULTS: Of the 20 UM cases 18 gave MLPA results from FFPE material that passed quality control thresholds. When chromosome 3 copy number was classified successfully (loss, disomy or gain) using FFPE material, the corresponding frozen sample showed concordance in 100% of cases. However, even when FFPE samples passed quality thresholds, chromosome arm copy numbers for 3p and 3q were "unclassifiable" in 28% and 11% of cases, respectively. This compared to "unclassifiable" cases in 0% and 6% of the frozen UM samples.
CONCLUSIONS: Whenever possible, fresh or snap-frozen tissue should be used for UM genetic prognostic testing by MLPA. When only fixed tissue is available, MLPA can be used to determine reliably chromosome 3 copy number. However, some tumors will be unclassifiable where DNA quality is poor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22427594     DOI: 10.1167/iovs.12-9584

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  16 in total

1.  Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture.

Authors:  B Damato
Journal:  Eye (Lond)       Date:  2012-06-29       Impact factor: 3.775

2.  Combined mutation and copy-number variation detection by targeted next-generation sequencing in uveal melanoma.

Authors:  Kyra N Smit; Natasha M van Poppelen; Jolanda Vaarwater; Robert Verdijk; Ronald van Marion; Helen Kalirai; Sarah E Coupland; Sophie Thornton; Neil Farquhar; Hendrikus-Jan Dubbink; Dion Paridaens; Annelies de Klein; Emine Kiliç
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

3.  Host pigment epithelium-derived factor (PEDF) prevents progression of liver metastasis in a mouse model of uveal melanoma.

Authors:  John M Lattier; Hua Yang; Susan Crawford; Hans E Grossniklaus
Journal:  Clin Exp Metastasis       Date:  2013-06-22       Impact factor: 5.150

Review 4.  Uveal melanoma: From diagnosis to treatment and the science in between.

Authors:  Chandrani Chattopadhyay; Dae Won Kim; Dan S Gombos; Junna Oba; Yong Qin; Michelle D Williams; Bita Esmaeli; Elizabeth A Grimm; Jennifer A Wargo; Scott E Woodman; Sapna P Patel
Journal:  Cancer       Date:  2016-03-15       Impact factor: 6.860

5.  Application of NeuroTrace staining in the fresh frozen brain samples to laser microdissection combined with quantitative RT-PCR analysis.

Authors:  Seico Benner; Masaki Kakeyama; Toshihiro Endo; Wataru Yoshioka; Chiharu Tohyama
Journal:  BMC Res Notes       Date:  2015-06-20

6.  ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma.

Authors:  Yoshihiko Murata; Yuko Minami; Reika Iwakawa; Jun Yokota; Shingo Usui; Koji Tsuta; Kouya Shiraishi; Shingo Sakashita; Kaishi Satomi; Tatsuo Iijima; Masayuki Noguchi
Journal:  Cancer Sci       Date:  2014-03-19       Impact factor: 6.716

7.  Small High-Risk Uveal Melanomas Have a Lower Mortality Rate.

Authors:  Rumana N Hussain; Sarah E Coupland; Helen Kalirai; Azzam F G Taktak; Antonio Eleuteri; Bertil E Damato; Carl Groenewald; Heinrich Heimann
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

8.  Comparison of microRNA deep sequencing of matched formalin-fixed paraffin-embedded and fresh frozen cancer tissues.

Authors:  Wei Meng; Joseph P McElroy; Stefano Volinia; Jeff Palatini; Sarah Warner; Leona W Ayers; Kamalakannan Palanichamy; Arnab Chakravarti; Tim Lautenschlaeger
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

9.  Copy-number variation of MCL1 predicts overall survival of non-small-cell lung cancer in a Southern Chinese population.

Authors:  Jieyun Yin; Yangkai Li; Hao Zhao; Qin Qin; Xiaorong Li; Jiao Huang; Yun Shi; Shufang Gong; Li Liu; Xiangning Fu; Shaofa Nie; Sheng Wei
Journal:  Cancer Med       Date:  2016-06-05       Impact factor: 4.452

10.  Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.

Authors:  Chantal E Hargreaves; Chisako Iriyama; Matthew J J Rose-Zerilli; Sietse Q Nagelkerke; Khiyam Hussain; Rosalind Ganderton; Charlotte Lee; Lee R Machado; Edward J Hollox; Helen Parker; Kate V Latham; Taco W Kuijpers; Kathleen N Potter; Sarah E Coupland; Andrew Davies; Michael Stackpole; Melanie Oates; Andrew R Pettitt; Martin J Glennie; Mark S Cragg; Jonathan C Strefford
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.